Dimeric inhibin serum values as markers of ovarian activity in pill- free intervals

Contraception

Volumn 57, Issue 1, 1998, Pages 45-48

  Renier, M A ^a   Vereecken, A ^b   Van Herck, E ^b   Straetmans, D ^b   Ramaekers, P ^b   Vanderheyden, J ^b   Degezelle, H ^b   Buytaert, P ^b  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b NONE

Author keywords

Inhibin A; Inhibin B; Ovarian activity; Pill free interval

Indexed keywords

BIOCHEMICAL MARKER; CONTRACEPTIVE AGENT; ESTRADIOL; FOLLITROPIN; INHIBIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; DRUG EFFICACY; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; IMMUNORADIOMETRIC ASSAY; LUTEINIZING HORMONE BLOOD LEVEL; ORAL CONTRACEPTION; OVARY FOLLICLE CELL; OVARY FUNCTION; PROGESTERONE BLOOD LEVEL;

BELGIUM; BIOLOGY; CLINICAL RESEARCH; CONTRACEPTION; CONTRACEPTIVE METHODS--PHARMACODYNAMICS; DEVELOPED COUNTRIES; ENDOCRINE SYSTEM; EUROPE; FAMILY PLANNING; GENITALIA; GENITALIA, FEMALE; HORMONES; ORAL CONTRACEPTIVES, COMBINED--PHARMACODYNAMICS; ORAL CONTRACEPTIVES--PHARMACODYNAMICS; OVARIAN EFFECTS; OVARY; PHYSIOLOGY; PITUITARY HORMONES; RESEARCH METHODOLOGY; RESEARCH REPORT; UROGENITAL SYSTEM; WESTERN EUROPE;

ADULT; BIOLOGICAL MARKERS; COHORT STUDIES; DIMERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; ESTRADIOL; ESTRADIOL CONGENERS; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; INHIBINS; LUTEINIZING HORMONE; OVARIAN FOLLICLE; PROGESTERONE; PROGESTINS; TIME FACTORS;

EID: 0031921303     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(97)00206-0     Document Type: Article

References (10)

1. 1. Morris SE, Groom GV, Cameron ED, Buckingham MS, Everitt JM, Elstein M. Studies on low-dose contraceptives: plasma hormone changes in relation to deliberate pill (Microgynon 30) omission. Contraception 1979;20: 61-9.
2. 2. Killick SR, Bancroft K, Oelbaum S, Morris J, Elstein M. Extending the duration of the pill-free interval during combined oral contraception. Adv Contracept 1990;6: 33-40.
3. 3. Elstein M. Consensus paper: low-dose contraceptive formulations: is further reduction in steroid dosage justified? Adv Contracept 1994;10:1-4.
4. 4. Elstein M, Bristow PG, Hewitt KJ. Effects of a low estrogen oral contraceptive on urinary excretion of luteinising hormone and ovarian steroids. Br Med J 1974;1:11-3.
5. 5. Tayob Y, Adams J, Jacobs HS. Ultrasound demonstration of an increased incidence in functional ovarian cysts in progesterone-only pill users. Br J Obstet Gynaecol 1985;92:1003-9.
6. 6. Killick S, Eyong E, Elstein M. Ovarian follicular development in oral contraceptive cycles. Fertil Steril 1987; 48:409-13.
7. 7. Hamilton CJCM, Hoogland HJ. Longitudinal ultrasonographic studies of the ovarian suppressive activity of a low-dose triphasic oral contraceptive during correct and incorrect pill intake. Am J Obstet 1989;161:1159-62.
8. 8. Klein NA, Illingworth PJ, Groome NP, McNeilly AS, Battaglia DE, Soules MR. Decreased inhibin B secretion is associated with the monotrophic FSH rise in older, ovulatory women: a study of serum and follicular fluid levels of dimeric inhibin A and B in spontaneous menstrual cycles. J Clin Endocrinol Metab 1996;81: 2742-5.
9. 9. Schoot DC, Harlin J, Shoham Z. Recombinant follicle-stimulating hormone and ovarian response in gonadotrophin deficient women. Hum Reprod 1994;9:1237-42.
10. 10. Groome NP, Illingworth PJ, O'Brien M. Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 1996;81:1401-5.